New painless vaccine technology targets viruses
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
List view / Grid view
Learn how Kindeva and Emervax are advancing vaccine delivery with painless, needle-free technology designed to improve accessibility and uptake worldwide.
A breakthrough in molecular imaging could transform how doctors target solid tumours, offering more personalised and effective treatment options.
A previously unknown process by which pathogens breach immune defences offers promise for treating infectious diseases.
Australian researchers analyse the way specialised white blood cells produce an immune response, which could lead to the development of preventative treatments for cancer and infectious diseases.
The natural process of removing damaged cell parts could present an alternative to antibiotics, especially where bacteria have become resistant to existing drugs.
A new study has found that mycobacteria are associated with red blood cells at lung infection sites, an interaction that has escaped scientists for 140 years.
A recent study has shown that antiretroviral therapy timing impacts the animal version of HIV and latent tuberculosis.
A research team have created a new strategy for developing an effective vaccine against a widespread form of tuberculosis.
Using synthetic chemistry, researchers have fused hydrophobic adjuvants with water-soluble proteins to create a new type of vaccine.
This article lists three of the most recent advances in pre-clinical HIV research and vaccine development.
Tested on two assays, researchers have shown that Redx03863 and Redx04739 can combat tuberculosis and do not lead to resistance.
Researchers have developed MorphEUS, a technology to identify new drugs that combat M. tuberculosis by revealing how compounds destroy the bacteria.
A study has shown that the COVID-19 pandemic has resulted in a high level of research donations, making the condition the third most funded disease on average by year.
Researchers have used a new method to understand how antibiotics fight TB, which can guide future drug developments.
A new study has identified a class of immune cells that respond to tuberculosis, indicating a drug target for the condition.